JP7015169B2 - 機能性ミトコンドリアで富化された哺乳動物細胞 - Google Patents

機能性ミトコンドリアで富化された哺乳動物細胞 Download PDF

Info

Publication number
JP7015169B2
JP7015169B2 JP2017544332A JP2017544332A JP7015169B2 JP 7015169 B2 JP7015169 B2 JP 7015169B2 JP 2017544332 A JP2017544332 A JP 2017544332A JP 2017544332 A JP2017544332 A JP 2017544332A JP 7015169 B2 JP7015169 B2 JP 7015169B2
Authority
JP
Japan
Prior art keywords
bone marrow
composition
mitochondrial
cells
marrow cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017544332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507690A (ja
JP2018507690A5 (enExample
Inventor
イヴジ－オハナ，ナタリー
ハラヴィー，ウリエル
Original Assignee
ミノヴィア セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミノヴィア セラピューティクス リミテッド filed Critical ミノヴィア セラピューティクス リミテッド
Publication of JP2018507690A publication Critical patent/JP2018507690A/ja
Publication of JP2018507690A5 publication Critical patent/JP2018507690A5/ja
Priority to JP2021142214A priority Critical patent/JP7263455B2/ja
Application granted granted Critical
Publication of JP7015169B2 publication Critical patent/JP7015169B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
JP2017544332A 2015-02-26 2016-02-24 機能性ミトコンドリアで富化された哺乳動物細胞 Active JP7015169B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021142214A JP7263455B2 (ja) 2015-02-26 2021-09-01 機能性ミトコンドリアで富化された哺乳動物細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562120907P 2015-02-26 2015-02-26
US62/120,907 2015-02-26
PCT/IL2016/050205 WO2016135723A1 (en) 2015-02-26 2016-02-24 Mammalian cells enriched with functional mitochondria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021142214A Division JP7263455B2 (ja) 2015-02-26 2021-09-01 機能性ミトコンドリアで富化された哺乳動物細胞

Publications (3)

Publication Number Publication Date
JP2018507690A JP2018507690A (ja) 2018-03-22
JP2018507690A5 JP2018507690A5 (enExample) 2019-04-04
JP7015169B2 true JP7015169B2 (ja) 2022-02-02

Family

ID=56789318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017544332A Active JP7015169B2 (ja) 2015-02-26 2016-02-24 機能性ミトコンドリアで富化された哺乳動物細胞
JP2021142214A Active JP7263455B2 (ja) 2015-02-26 2021-09-01 機能性ミトコンドリアで富化された哺乳動物細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021142214A Active JP7263455B2 (ja) 2015-02-26 2021-09-01 機能性ミトコンドリアで富化された哺乳動物細胞

Country Status (5)

Country Link
US (3) US20180030413A1 (enExample)
EP (1) EP3261649A4 (enExample)
JP (2) JP7015169B2 (enExample)
IL (2) IL254071B2 (enExample)
WO (1) WO2016135723A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282198B2 (en) 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
CA2952121A1 (en) 2014-06-13 2015-12-17 Childrens' Medical Center Corporation Products and methods to isolate mitochondria
US20170151287A1 (en) 2015-11-30 2017-06-01 Flagship Ventures Management, Inc. Methods and compositions of chondrisomes
ES3057779T3 (en) 2016-01-15 2026-03-04 Childrens Medical Ct Corp Therapeutic use of mitochondria and combined mitochondrial agents
WO2018088874A1 (ko) * 2016-11-14 2018-05-17 주식회사 파이안바이오테크놀로지 외래 미토콘드리아를 세포로 전달하는 방법
CN109983120A (zh) 2016-11-14 2019-07-05 白雁生物技术公司 含有外源线粒体的天然杀伤细胞和含有其的药物组合物
CN110022884A (zh) * 2016-11-30 2019-07-16 白雁生物技术公司 含有线粒体的药物组合物
US20200023005A1 (en) * 2017-03-26 2020-01-23 Minovia Therapeutics Ltd. Mitochondrial compositions and methods for treatment of skin and hair
WO2019183042A1 (en) * 2018-03-20 2019-09-26 Unity Biotechnology, Inc. Autologous mitochondrial extraction and expansion
WO2019186553A1 (en) * 2018-03-27 2019-10-03 Minovia Therapeutics Ltd. Methods for elevation of lipid and cholesterol metabolism
WO2020021541A1 (en) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria
US12502408B2 (en) * 2018-07-22 2025-12-23 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
US12329781B2 (en) 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
JP7524157B2 (ja) * 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
WO2020021539A1 (en) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
EP3823644A4 (en) * 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
WO2020021535A1 (en) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
WO2020021537A1 (en) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of liver diseases
KR20210045435A (ko) * 2018-08-14 2021-04-26 이멜 바이오테라퓨틱스, 인코포레이티드. 미토콘드리아 질환 또는 장애 및 헤테로플라스미를 치료하기 위한 방법 및 조성물
CN112912087A (zh) * 2018-09-14 2021-06-04 卢卡科学株式会社 线粒体向淋巴器官中的移植以及用于该移植的组合物
JP2022517784A (ja) * 2019-01-11 2022-03-10 フィジーン、エルエルシー 線維芽細胞再生細胞
JP7745544B2 (ja) * 2019-10-24 2025-09-29 イメル バイオセラピューティクス，インク． ミトコンドリアｄｎａ中のマクロヘテロプラスミー及びミクロヘテロプラスミーを検出するための方法
US12091684B2 (en) * 2020-02-14 2024-09-17 Hackensack Meridian Health, Inc. Platelet-derived mitochondria treatment and method of generating multipotent cells
TWI789723B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療或/及預防腎臟損傷相關疾病之用途
MX2022012157A (es) * 2020-03-31 2023-02-15 Minovia Therapeutics Ltd Celulas geneticamente modificadas enriquecidas con mitocondrias y usos de estas.
CN115427052A (zh) * 2020-03-31 2022-12-02 米诺维亚治疗公司 线粒体加强疗法
US20230190822A1 (en) * 2020-05-05 2023-06-22 Pluri Biotech Ltd. Methods and compositions for enrichment of target cells
AU2023304232A1 (en) * 2022-07-08 2025-01-23 Mitrix Bio, Inc. Systems and methods for growing mitochondria and coating thereof
EP4598550A1 (en) * 2022-10-06 2025-08-13 Mitrix Bio, Inc. Formulations and methods for cellular therapies involving chimeric antigen receptors
CN116478920B (zh) * 2023-05-05 2025-03-25 重庆理工大学 一种离体线粒体的体外储存方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107285A1 (en) 2010-10-28 2012-05-03 Searete Llc A Limited Liability Corporation Of The State Of Delaware Mitochondrial enhancement of cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012050A2 (en) 2001-07-31 2003-02-13 Northeastern University Mitochondrial genome replenishment
US20050153381A1 (en) * 2002-02-14 2005-07-14 Marusich Michael F. Immunocapture of mitochondrial protein complexes
AU2004238375A1 (en) 2003-05-13 2004-11-25 The Regents Of The University Of Colorado Diagnostic and therapeutic treatments related to mitochondrial disorders
US7407800B1 (en) 2003-09-19 2008-08-05 Pierce Biotechnology, Inc. Method for the isolation of intact mitochondria from cells
CA2688125A1 (en) 2007-05-02 2008-11-13 The Mclean Hospital Corporation Methods and compositions for mitochondrial replacement therapy
WO2008152640A2 (en) 2007-06-13 2008-12-18 Pluristem Ltd. Three dimensional biocompatible scaffolds for ex-vivo expansion and transplantation of stem cells
WO2009154770A2 (en) 2008-06-18 2009-12-23 The Texas A & M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
US20110105359A1 (en) 2009-10-30 2011-05-05 Xenotech, Llc Cryopreservation of cells and subcellular fractions
EP2726601B1 (en) 2011-06-29 2018-12-26 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US20130022666A1 (en) * 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
IL282198B2 (en) * 2011-09-11 2025-11-01 Minovia Therapeutics Ltd Compositions of functional mitochondria and uses thereof
US8648034B2 (en) * 2011-12-09 2014-02-11 Changhua Christian Hospital Method and applications of peptide-mediated mitochondrial delivery system
WO2013149064A1 (en) * 2012-03-30 2013-10-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells
US10702556B2 (en) 2012-05-16 2020-07-07 Minovia Therpautices Ltd. Compositions and methods for inducing angiogenesis
WO2016008937A1 (en) * 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107285A1 (en) 2010-10-28 2012-05-03 Searete Llc A Limited Liability Corporation Of The State Of Delaware Mitochondrial enhancement of cells

Also Published As

Publication number Publication date
US20180030413A1 (en) 2018-02-01
JP2018507690A (ja) 2018-03-22
JP7263455B2 (ja) 2023-04-24
US20200239850A1 (en) 2020-07-30
IL254071B1 (en) 2023-09-01
IL299482A (en) 2023-02-01
US11441124B2 (en) 2022-09-13
EP3261649A4 (en) 2018-08-15
US20190330595A1 (en) 2019-10-31
IL299482B2 (en) 2025-02-01
CA2977341A1 (en) 2016-09-01
WO2016135723A1 (en) 2016-09-01
JP2021191776A (ja) 2021-12-16
IL254071A0 (en) 2017-10-31
IL299482B1 (en) 2024-10-01
EP3261649A1 (en) 2018-01-03
IL254071B2 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
JP7263455B2 (ja) 機能性ミトコンドリアで富化された哺乳動物細胞
US20240415894A1 (en) Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria
US12502408B2 (en) Mitochondrial augmentation therapy for primary mitochondrial diseases
US12239672B2 (en) Mitochondrial augmentation therapy of ocular diseases
US12551504B2 (en) Mitochondrial augmentation therapy of pancreatic diseases
US20210252075A1 (en) Mitochondrial augmentation therapy of liver diseases
CA2977341C (en) Mammalian cells enriched with functional mitochondria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220121

R150 Certificate of patent or registration of utility model

Ref document number: 7015169

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250